During RedChip's overview with Virax Biolabs (Nasdaq: VRAX), CEO James Foster discussed the diagnostic gap behind Long COVID and chronic fatigue. Foster outlines ViraxImmune, the company's in-development test for post-acute infection syndromes — a category he says carries a major burden in the U.S., and where patients are currently diagnosed mostly through symptoms and exclusion. Watch the overview: redchip.news/4fNqVLp Virax Biolabs is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN $JNJ

In RedChip's exclusive interview with Alliance Entertainment (Nasdaq: AENT),Ken Glaser, SVP of Sales, discussed independent retail's role in the company's broader distribution strategy, noting that these stores often surface consumer demand signals early. Management also discussed year-over-year growth in physical movie and collectibles revenue in Q2 FY26, and pointed to new store openings and younger consumers entering the channel as factors shaping the category. Glaser points to new store openings, younger consumers entering the channel, and artists like Taylor Swift and Olivia Rodrigo leaning into exclusive variants and limited releases as structural — not cyclical — demand drivers. 🔗 Watch the full interview: lnkd.in/eUPcHz2P Alliance Entertainment is a client of RedChip. Not investment advice. Do your own due diligence. $SONY $DIS $PARA $WBD $NTDOY

🧬 Biovie Inc. (Nasdaq: BIVI) CEO Cuong Do walks through the topline results of BioVie's Phase 2 ADDRESS LC trial for bezisterim in Long COVID, and the headline finding is specificity: the drug appears to help patients on whatever symptom they actually have. Do notes 21 of the 22 clinical endpoints assessed favored bezisterim treatment, which he says makes the result unlikely to be due to chance. Do frames this alongside BioVie's recent positive Phase 2 Parkinson's data as validating a broader thesis: that bezisterim is having a real biological effect on CNS function by targeting inflammation and insulin resistance, a mechanism the company believes underlies multiple neurodegenerative and inflammatory conditions. On market size, Do says the trial results reshape BioVie's own estimate of the addressable Long COVID population — up from roughly 4 million severely disabled Americans to potentially 80% of the ~20 million adults living with Long COVID symptoms, a shift he says makes the commercial opportunity substantially larger than originally modeled. 🔗 Watch the full interview: redchip.news/4yFvmzB Biovie Inc. is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN

🧠 Lantern Pharma (NASDAQ: LTRN): http://http://withZeta.ai Positions AI at the Center of Cancer Drug Discovery 90% of new drug discoveries fail in the clinic — costing billions of dollars and decades of lost time. At Nasdaq MarketSite in New York City, Lantern Pharma unveiled withZeta.ai — the company's multi-agentic AI co-scientist platform designed for oncology research and precision drug development. The announcement is notable for investors because withZeta.ai is built to reason across clinical trials, scientific literature, molecular databases, and biomarker data simultaneously — spanning 438 cancer types and compressing years of research into hours. 🔬 Key platform differentiators highlighted: • Multi-agentic AI architecture designed to think alongside researchers • Cross-analysis of oncology datasets, trials, and scientific literature • Proprietary AI infrastructure developed over more than a decade • Focus on cancers with limited treatment options and high unmet need For investors, the key takeaway is Lantern Pharma's positioning at the intersection of artificial intelligence and precision oncology, pairing its clinical-stage oncology pipeline with a differentiated AI-driven discovery platform. LTRN is a client of RedChip. To learn more, click the link! redchip.news/4ec5AKR Lantern Pharma is a client of RedChip. Not investment advice. Do your own due diligence. #LTRN #LanternPharma #AI #BiotechStocks #PrecisionOncology #CancerResearch #DrugDiscovery #ArtificialIntelligence #HealthcareInnovation #Nasdaq #SmallCapStocks

🤖 In this company overview, Exyn Technologies (Nasdaq: EXYN) CEO Ben Williams draws a clear line around what Exyn actually is: not a drone manufacturer, not a robotics provider, but the autonomy software layer — ExynAI, delivered through a payload called the Exyn Nexus. Williams frames the business around four pillars: underground mining, geospatial data collection, OEM software licensing, and government/defense. The common thread is what he calls "continuous ubiquitous digitization," solving physical industries' data problem by digitizing in real time. External users now run more than 1,000 autonomous missions per month across 30+ countries, in conditions Williams says have stress-tested the system in every edge case imaginable. 🔗 Watch the company overview: youtube.com/watch?v=EFDMCKBj… Exyn Technologies is a client of RedChip. Not investment advice. Do your own due diligence. $AVAV $TRMB $TDY $KTOS $OUST $UMAC

OBook Holdings (Nasdaq: OWLS) founder and CEO Darren Wang explains why regulatory licensing is OwlTing's biggest edge over future competitors. The company has spent over four years securing more than 40 U.S. money transmitter licenses, with additional licenses in Europe and across Asia including Japan, Singapore, and Hong Kong. Wang says this global licensing infrastructure is difficult to replicate quickly, positioning OwlTing as a compliant backbone for banks and fintech companies moving money across borders using stablecoins. Watch the full interview: redchip.news/4wpqkFT OBook Holdings is a client of RedChip. Not investment advice. Do your own due diligence. $COIN $PYPL $XYZ $NATL $MARA $RIOT $MSTR $NVDA

RedChip shared a Q2 field update from CEO Christopher Gerteisen on Nova Minerals' (NYSE American: NVA) Estelle project in Alaska. Management reported that the 2026 winter freight haul season was completed ahead of schedule and on budget, with mining and processing equipment now staged on-site. Management discussed the company's antimony production plan, which includes on-site ore sorting ahead of downstream processing at Port MacKenzie. Learn more, and read our disclosures: nvainfo.com Nova Minerals is a client of RedChip. Not investment advice. Do your own due diligence. $MP $PPTA $TECK $KGC $CTGO $XAU $XAUUSD

Recently on RedChip's Webinar series, Nexalin Technology (Nasdaq: NXL) CEO Mark White uses a simple analogy to explain a complex technology: your brain as an organic supercomputer. White describes the company's deep intracranial frequency stimulation (DIFS™) platform as providing a "reboot and reset" for brain networks he says have been disrupted by mental health disease — much like restarting a computer at home, but applied to the midbrain regions he states other non-invasive stimulators can't reach. He contrasts Nexalin's approach with most existing neurostimulation devices, which he says are limited by voltage and therefore can only affect the surface of the brain. 🔗 Learn more about Nexalin Technology: redchip.news/4AhyqDZ Nexalin Technology is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $AMGN $REGN $GILD $MRNA

⏰ One Week Away: ASP Isotopes (NASDAQ: $ASPI) Live Investor Webinar, Tuesday, November 3 at 4:15 PM ET The ASPI webinar is one week away. The company’s proprietary enrichment platform is moving from proof to scale, with three plants operating in Pretoria and measurable gains in performance. Management will walk through progress across the platform and what comes next for each business. 📈 What’s driving the story: Three enrichment plants built and operating in Pretoria Silicon-28 plant uptime improved from 58% in May to 90% in July Ytterbium-176 enriched from feedstock above 13% to above 94%, with continuous-processing scale-up underway More than 10,000 doses delivered across four PET Labs radiopharmacies, with expansion in South Africa and the U.S. Alpa Theranostics has five tumor types in preclinical development, with the first candidate targeted for human trials within 12 months Secure your seat today to hear management’s view of the road ahead. 🔗 Register here: redchip.news/4hUxXAi #ASPI #ASPIsotopes #Isotopes #NuclearMedicine #Helium #NuclearEnergy #CriticalMaterials #NasdaqStocks #InvestorWebinar #SmallCapInvesting

🧠 Recently On RedChip's Interview Series: Nexalin Technology (Nasdaq: NXL) CEO Mark White sits down to cover the company's DIFS™ brain stimulation platform, its Alzheimer's trial data, its NeuroCare® virtual clinic, and its insomnia trial strategy. White describes DIFS™ as a non-invasive, drug-free stimulation technology that produces relief with no reported side effects or adverse events. He notes that 80% of the company's published trials include neuroimaging data to verify biomarker changes. On Alzheimer's specifically, White cites three recent trials showing improved memory, word recognition and comprehension, and says the data shows the technology slowing disease progression. 🔗 Watch the full interview: youtube.com/watch?v=CLtBwCVI… Nexalin Technology is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $AMGN $REGN $GILD $MRNA

VENU Holding Corp. (NYSE American: VENU) CEO JW Roth explains why he believes VENU's business model is hard to replicate. Asked what it would take for a competitor to copy VENU, Roth points first to the municipal relationships — he states it took five years to build the network of 40 municipalities VENU works with today. He adds that a competitor would also need the roughly $200 million in capital VENU raised at its founding, plus the operational expertise to execute the model. 🔗 Learn more about VENU Holding Corp. redchip.news/46952lm VENU Holding Corp. is a client of RedChip. Not investment advice. Do your own due diligence. $TKO $MSGE $LYV $SPHR

RedChip hosted a webinar with Paul Mann, CEO of ASP Isotopes (Nasdaq: ASPI). Mann discussed global supply challenges for critical materials, including isotopes such as Silicon-28 and Ytterbium-176, which have historically depended on Russia and China, as well as disruptions in the helium market tied to Qatar. He framed addressing these supply bottlenecks as central to the company's business strategy. Learn more: redchip.news/4yU8SvF ASP Isotopes is a client of RedChip. Not investment advice. Do your own due diligence. $SMR $NNE $OKLO $UUUU $CEG $VST $CCJ $UEC $LEU $GEV $BEP

🛰️ In March 2026, missile strikes on Qatar wiped out nearly a third of the world's helium supply. Helium isn't a commodity you swap out: it's critical to missiles, rockets, space systems, and satellites — core U.S. national defense infrastructure. Noble Africa (Potential merger with Endara Life Sciences | Nasdaq: NDRA) owns one of the most prolific helium assets in the world, now under development specifically to help meet U.S. supply demand. The project is anchored by funding from the U.S. Development Finance Corporation, and Noble Africa has now announced a proposed merger with Nasdaq-listed ENDRA (NDRA). 🔗 Watch the overview: redchip.news/46vrqFS Noble Africa is a client of RedChip. Not investment advice. Do your own due diligence. $SMR $NNE $OKLO $UUUU $CEG $VST $CCJ $UEC $LEU $GEV $BEP

🧬 Recently covered by RedChip: $40M+ Revenue Diagnostics Company Valued at Roughly $6M Advances CGM+ and Enters AI Data Center Cooling Trinity Biotech (Nasdaq: TRIB) generates roughly $40 to $50 million in annual revenue from a global diagnostics portfolio built over more than 30 years, yet the market values the company at approximately $6 million. A new RedChip article examines the turnaround underway since new management took over in late 2023 and the two larger markets the company is now pursuing. In the first quarter of 2026, revenue rose 43% year over year to $10.8 million, and gross margin improved to 35.4% from 25.2%, as the company consolidated manufacturing and shifted production to lower-cost locations. 📌 Why Investors Should Be Watching: - CGM+ clinical data: In pre-pivotal testing covering more than 5,000 hours of sensor wear, Trinity reported that its multi-sensor platform identified compression-induced false low readings, a known limitation of glucose-only monitors - Trinovium: The new subsidiary applies Trinity's high-purity fluid manufacturing to AI data center liquid cooling, a market projected to grow from approximately $4 billion in 2026 to $27 billion by 2033, and has announced a collaboration with Echelon Data Centres - Diagnostics volume: Orders for more than two million TrinScreen HIV tests add volume to the core business as the manufacturing transition progresses CGM+ still has pivotal clinical development and regulatory submissions ahead, and Trinovium has yet to reach commercialization, but both are being built on technology and infrastructure Trinity already owns. Read the full article: redchip.news/4iR1V9g Trinity Biotech is a client of RedChip. Not investment advice. Do your own due diligence. $DXCM $MDT $TNDM $ABT $SAN $PODD

Hawkeye Digital (OTC: HWKE): What if you could invest before things get too big? President David Wachsman explains "Vanguard Tech," Hawkeye's term for the earliest, most sophisticated technology bets — the logic being that the more cutting-edge something is, the fewer people understand it well enough to invest intelligently. Learn more: redchip.news/3S8OTsD Hawkeye Digital is a client of RedChip. Not investment advice. Do your own due diligence. $GLXY $CRCL $BLSH $COIN $MSTR $MARA $RIOT

RedChip recently hosted an interview with Philippe Calais, CEO of TransCode Therapeutics (Nasdaq: RNAZ). Calais discussed the company's transition into a three-platform oncology company over the past nine months and the next phase of clinical development for lead candidate TTX-MC138. The conversation covered results from the Phase 1a trial, the ongoing Phase 2a trial in colorectal cancer patients, and the company's delivery platform, which Calais described as supporting multiple therapeutic payload types and representing a potential long-term partnering opportunity. Watch the full interview: redchip.news/4xl2f4e TransCode Therapeutics is a client of RedChip. Not investment advice. Do your own due diligence. $MRNA $ARWR $ALNY $IONS $SLN $SRPT

RedChip's overview of Clinch Resources (TSX: CLCH) covers the company's recent entry into production at its surface mining operation. Management, led by CEO Brett Young, discussed the company's decade-long asset consolidation process, its fully permitted and vertically integrated platform, and its position as a domestic supplier to U.S. steel producers using American assets. The conversation also touched on current conditions in the global metallurgical coal market.. Clinch is entering the market as a 100% U.S.-based supplier at a moment of structural undersupply in the global met coal market. Watch the full overview: redchip.news/44gPATg Clinch Resources is a client of RedChip. Not investment advice. Do your own due diligence. $CEIX $NRP $SXC $BHP $TECK $CLF $NUE $STLD $MT $RS $VALE $FCX $ARLP

🔬 Virax Biolabs (Nasdaq: VRAX) CEO James Foster lays out the investor thesis in one line: a large unmet diagnostic need, differentiated T-cell biology, a defined U.S. commercial pathway, and a more disciplined corporate position to execute from. 🧬 The company's shifting focus to ViraxImmune — a functional immune test targeting post-acute infection syndromes like Long COVID — with a planned U.S. lab-developed test pathway as the near-term commercial route. 📊 Full webinar replay: redchip.news/4riTXaZ Virax Biolabs is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN $JNJ

Alliance Entertainment (Nasdaq: AENT) isn't just a distributor — it's an engine powering the distribution of vinyl, video games, collectibles, and more. With a capital-light model, expanding exclusive IP, and strategic retail partnerships (Amazon, Walmart, Barnes & Noble, and other major chains), Alliance Entertainment is positioned to scale profitability in the collectibles and entertainment market. Watch our brief overview: redchip.news/4oPbtBa Alliance Entertainment is a client of RedChip. Not investment advice. Do your own due diligence. $SONY $DIS $PARA $WBD $NTDOY

60 Degrees Pharmaceuticals (Nasdaq: SXTP): Advancing Tick-Borne Disease Treatment RedChip's 30-second overview of 60 Degrees Pharmaceuticals' work on tick-borne disease treatment, as infections like babesiosis continue to rise. What was covered: - The company's clinical trial results for relapsing babesiosis, in which all patients in the study were reported cured following treatment with tafenoquine - Ongoing trials at leading hospital sites - The company's own estimates of the market opportunity, including potential peak annual sales and total revenue over its exclusivity period Watch our 30-Sec Overview: redchip.news/4saEbhY 60 Degrees Pharmaceuticals is a client of RedChip. Not investment advice. Do your own due diligence. $VRTX $LLY $NVO $PFE $REGN